Dental Tribune Untited Kingdom Edition

Do you have an opinion or some- thing to say on any Dental Tribune UK article? Or would you like to write your own opinion for our guest comment page? If so don’t hesitate to write to: The Editor, Dental Tribune UK Ltd, 4th Floor, Treasure House, 19-21 Hatton Garden, London, EC1 8BA Or email: lisa@dentaltribuneuk.com Editorial comment Duraphat 50 mg/ml Dental Suspension. Active ingredients: 1ml of suspension contains 50mg Sodium Fluoride equivalent to 22.6mg of Fluoride (22,600ppm F) Indications: Prevention of caries, desensitisation of hypersensitive teeth. Dosage and administration: Recommended dosage for single application: for milk teeth: up to 0.25ml (=5.65mg Fluoride), for mixed dentition: up to 0.40ml (=9.04 Fluoride), for permanent dentition: up to 0.75ml (=16.95 Fluoride). For caries prophylaxis the application is usually repeated every 6 months but more frequent applications (every 3 months) may be made. For hypersensitivity, 2 or 3 applications should be made within a few days. Contraindications: Hypersensitivity to colophony and/or any other constituents. Ulcerative gingivitis. Stomatits. Bronchial asthma. Special warnings and special precautions for use: If the whole dentition is being treated the application should not be carried out on an empty stomach. On the day of application other high fluoride preparations such a fluoride gel should be avoided. Fluoride supplements should be suspended for several days after applying Duraphat. Interactions with other medicines: The presence of alcohol in the Duraphat formula should be considered. Undesirable effects: Oedematous swelling has been observed in subjects with tendency to allergic reactions.The dental suspension layer can easily be removed from the mouth by brushing and rinsing. In rare cases, asthma attacks may occur in patients who have bronchial asthma. Legal classification: POM. Product licence number: PL 00049/0042. Product licence holder: Colgate-Palmolive (U.K.) Ltd, Guildford Business Park, Middleton Road, Guildford, Surrey GU2 8JZ. Price: £22.70 exclVAT (10ml tube) Date of revision of text: July 2008. 1 Marinho et al. (2002); Cochrane Database Syst. Rev. no3. 2 Delivering Better Oral Health - An evidence-based toolkit for prevention, Second Edition, Department of Health, July 2009. In surgery treatment for caries prevention Clinically proven caries efficacy1 – 33% reduction in dmfs – 46% reduction in DMFT  Quick and easy application Temporary light tint for visual control  Duraphat® Dental Suspension FluorideVarnish ® ® lighter tint New www.colgateprofessional.co.uk Applying fluoride varnish containing 22,600ppm F is a recommended intervention in ‘Delivering Better Oral Health – An evidence-based toolkit for prevention’2 ® A ccording to a new study, Metformin Prevents the Development of Oral Squamous Cell Carcinomas from Carcinogen-Induced Pre- malignant Lesions, published in Cancer Prevention Research, Metformin may protect against oral cancer. Metformin is the most widely used treatment for pa- tients with type 2 diabetes, and according to the study au- thors, scientists have noticed that “metformin reduces the growth of HNSCC (Head and neck squamous cell carcino- ma) cells and diminishes their mTORC1 activity by both AM- PK-dependent and -independ- ent mechanisms.” According to a report, J Sil- vio Gutkind, PhD, chief of the Oral and Pharyngeal Cancer Branch of the National Insti- tute of Dental and Craniofa- cial Research at the National Institutes of Health, and col- leagues induced premalignant lesions in laboratory mice; they then studied the effect of metformin on progression of these lesions to oral cancers. The scientists found that metformin reduced the size and number of carcinogen-in- duced oral tumoral lesions in mice and significantly reduced the development of squamous cell carcinomas by about 70 per cent to 90 per cent. DT Metformin may lower risk for oral cancer Metaformin tablets B ig congratu- lations to those who found themselves with a place in the top 50 most influ- ential people in dentistry, as voted for by members of the profession. James Goolnik made the top spot for the second year running, a big achievement and in recognition for the Heart Your Smile campaign which he founded last year; aiming to bring positivity back to the dental profession. Congratulations also go to Dean of the Peninsula Den- tal School and Dental Tribune editorial board member Liz Kay, number four in the list. Other notable names familiar to DT readers include Mhari Coxon (5), Elaine Halley (11), Nik Sisodia (23), Wyman Chan (35), Julian Webber (38) and Susie Sanderson (49). Thoughts are now also turning to the upcoming events prominent in the dental calendar: the Dental Awards (April 20), BDA Conference and Exhibition in Manches- ter (April 26-28) and the Clinical Innovations Confer- ence in London (May 18-19). I will be attending all three events – if you see me come over, say hi and let me know your thoughts on Dental Tribune!DT 3NewsApril 16-22, 2012United Kingdom Edition